Caprock Group LLC Purchases 1,013 Shares of Novo Nordisk A/S (NYSE:NVO)

Caprock Group LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,265 shares of the company’s stock after purchasing an additional 1,013 shares during the quarter. Caprock Group LLC’s holdings in Novo Nordisk A/S were worth $5,356,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP purchased a new position in Novo Nordisk A/S in the 3rd quarter worth $42,000. Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the third quarter worth $48,000. Finally, Dunhill Financial LLC boosted its position in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after buying an additional 311 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NVO shares. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $84.36 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $93.97 and its 200 day simple moving average is $113.62. The stock has a market cap of $378.56 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.